Flagship Biosciences, a pathology lab in Flagstaff, Arizona and TGen Drug Development (TD2), in Scottsdale, Arizona, have teamed up to provide drug discovery and development services to cancer researchers. Flagship Biosciences is a pharmaceutical services company that offers digital pathology to test diseased tissue samples for biotech, pharmaceutical, and medical device customers. TD2 is a non-profit contract research subsidiary of the Translational Genomics Research Institute in Phoenix.
Flagship offers cancer researchers computerized histopathology, the microscopic study of diseased tissue, which it says is important to the accurate diagnosis of cancer and other diseases from sample tissues. Flagship also provides experience in measuring epithelial–mesenchymal transition (EMT), the process in which tumor cells become highly invasive, migratory, and resistance to therapy.
In the partnership, TD2 offers its expertise as a contract research organization and its research technologies, with its experience in preclinical study execution, regulatory affairs assistance, and clinical trial design and management, to move new drugs toward regulatory approval.
Photo: Horia Varlan/Flickr
* * *
RSS - Posts
You must be logged in to post a comment.